10-Q: Harrow Reports Strong Revenue Growth, Faces Debt Maturity

Harrow, Inc. reported significant revenue growth in its branded ophthalmology segment for the first half of 2025, alongside improved cash flow from operations, but faces substantial debt maturities in early 2026.

Summary

• Total revenues for the six months ended June 30, 2025, increased to $111,573,000, up from $83,526,000 in the same period of 2024, a 33.6% increase.
• Product sales, net, rose to $111,402,000 for the first half of 2025, compared to $83,379,000 in the prior year period.
• The net loss for the six months ended June 30, 2025, improved to $(12,785,000) from $(20,038,000) in the corresponding 2024 period.
• Basic net loss per share improved to $(0.35) for the first half of 2025, compared to $(0.56) in the first half of 2024.
• Cash and cash equivalents increased to $52,963,000 as of June 30, 2025, from $47,247,000 at December 31, 2024.
• Net cash provided by operating activities significantly improved to $18,865,000 for the six months ended June 30, 2025, compared to net cash used of $(7,374,000) in the same period of 2024.
• The Oaktree Loan of $107,500,000 principal and 8.625% Senior Notes due 2026 of $75,000,000 principal are classified as current liabilities, maturing in January 2026 and April 2026, respectively.
• The company received a $34,900,000 jury verdict award, including $20,400,000 in punitive damages and $14,500,000 in actual damages, in a lawsuit against Ocular Science, Inc. and OSRX, Inc., though collection is uncertain and not recognized.
• The 2025 Incentive Stock and Awards Plan was adopted by stockholders on June 18, 2025.

Sentiment

Score: 6

Explanation: The company shows strong operational improvements with significant revenue growth in its branded segment and a positive shift in cash flow from operations. However, the substantial near-term debt maturities and the explicit 'going concern' warning introduce significant financial uncertainty and risk, tempering overall positive sentiment.

Positives

• Total revenues increased by 33.6% for the six months ended June 30, 2025, driven by strong performance in branded ophthalmology products.
• Net loss significantly improved to $(12,785,000) for the first half of 2025, compared to $(20,038,000) in the prior year.
• Cash and cash equivalents increased to $52,963,000 as of June 30, 2025.
• Net cash provided by operating activities showed a substantial positive swing, reaching $18,865,000 for the six months ended June 30, 2025, compared to a negative cash flow in the prior year.
• Branded segment revenue grew significantly, with IHEEZO sales increasing to $23,558,000 and VEVYE sales surging to $40,156,000 for the six months ended June 30, 2025.
• Secured a development and commercialization agreement with Samsung Bioepis Co., Ltd. for BYOOVIZ and OPUVIZ in the U.S. market.
• Acquired exclusive U.S. commercial rights to BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05% from Formosa Pharmaceuticals, with expected availability in Q4 2025.
• Launched the VEVYE Access for All patient program to improve patient access and affordability for VEVYE.
• Successfully closed discussions with the federal government regarding the New Jersey outsourcing facility (NJOF) quality system and 2024 Inspection.

Negatives

• The company reported a net loss of $(12,785,000) for the six months ended June 30, 2025.
• Current portion of notes payable increased significantly to $183,619,000 as of June 30, 2025, due to the reclassification of the Oaktree Loan and 2026 Notes, which mature in early 2026.
• The maturity of the Oaktree Loan ($107,500,000 principal due January 2026) and the 2026 Notes ($75,000,000 principal due April 2026) raises substantial doubt about the company's ability to continue as a going concern if refinancing or asset sales are unsuccessful.
• Branded gross margin decreased to 75.9% for the six months ended June 30, 2025, from 77.6% in the prior year, primarily due to increased fixed expenses and acquired product NDA amortizations related to TRIESENCE.
• ImprimisRx gross margin decreased to 64.3% for the six months ended June 30, 2025, from 67.2% in the prior year, due to product mix (more lower gross margin products) and sales discounts.
• Sales of 'Other branded products' decreased significantly to $6,169,000 for the six months ended June 30, 2025, from $20,553,000 in the prior year.
• Stockholders' equity decreased to $49,299,000 as of June 30, 2025, from $69,297,000 at December 31, 2024.

Risks

• The company is subject to regulatory standards, approvals, guidelines, and inspections, which could materially impact its ability to make, dispense, and sell certain products.
• The Oaktree Loan ($107,500,000 principal) and the 2026 Notes ($75,000,000 principal) mature in January 2026 and April 2026, respectively, raising substantial doubt about the company's ability to continue as a going concern if refinancing or asset sales are not successful.
• There is no assurance that the company will be able to refinance its indebtedness on acceptable terms or at all, or that any asset sales could be completed on a timely basis or on acceptable terms.
• Future regulatory actions, including potential enforcement actions by the FDA, could increase scrutiny and create negative publicity, limiting production and distribution of compounded products.
• Sales depend on coverage and reimbursement from government and commercial third-party payers, and ongoing pricing and reimbursement pressures could negatively affect profitability.
• The Inflation Reduction Act and other legislative/regulatory proposals aimed at lowering drug prices could materially adversely affect the business.
• Global economic conditions, including inflation, supply chain challenges, and geopolitical conflicts, may negatively affect the company's operations and increase operating expenses.
• Insolvency of distributors, customers, or suppliers could have a material adverse effect on product sales.
• Changes in U.S. trade policy, such as the imposition of significant tariffs on pharmaceuticals and raw materials, could increase costs, disrupt supply chains, and impair competitive position.

Future Outlook

Management expects to refinance the Oaktree Loan and the 2026 Notes during 2025 or soon thereafter, believing it is probable based on collateral strength and expected cash flows. The company anticipates using current cash and funds from operations, and potentially additional financing or asset sales, to support its business plan, including developing and commercializing drug candidates, integrating operations, and pursuing strategic transactions. The company expects BYQLOVI to be available in the fourth quarter of 2025. Management is also continuing to evaluate opportunities to reduce the size of its compounded formulary and transition ImprimisRx customers to FDA-approved products.

Management Comments

• "Management believes it is probable that the Company will be able to refinance the Oaktree Loan and the 2026 Notes based on the Companys collateral strength and expected cash flows from operations."
• "We believe we have built a tangible and intangible infrastructure that will allow us to scale revenues efficiently in the near and long-term."
• "We continue to review opportunities to reduce the size of our compounded formulary, improve and simplify our compounding capabilities, and transition other ImprimisRx customers from compounded formulations to Harrows FDA-approved products."

Industry Context

Harrow, Inc. operates in the North American ophthalmic disease management solutions market, a sector experiencing ongoing innovation and regulatory scrutiny. The company's strategy to shift from compounded formulations (ImprimisRx) to FDA-approved branded products aligns with broader industry trends towards standardized, approved medications, potentially reducing regulatory risks associated with compounding. The acquisition of commercial rights for BYQLOVI and the agreement with Samsung Bioepis for BYOOVIZ and OPUVIZ indicate a focus on expanding its branded portfolio, a common growth strategy for pharmaceutical companies seeking to capture larger market shares in specialized therapeutic areas. The 'VEVYE Access for All' program reflects the industry's increasing focus on patient access and affordability, often in response to public and regulatory pressures on drug pricing.

Comparison to Industry Standards

• Harrow's branded segment revenue growth of 70% for the six months ended June 30, 2025, significantly outpaces typical pharmaceutical industry growth rates, especially driven by IHEEZO and VEVYE, indicating strong market penetration for these specific products.
• The decline in ImprimisRx gross margin from 67.2% to 64.3% suggests challenges in the compounding segment, potentially due to competitive pressures, product mix shifts, or increased sales discounts, which may be below the higher margins typically seen in branded pharmaceutical sales.
• The company's strategic shift, exemplified by Project Beagle and the discontinuation of Klarity-C, aligns with a trend among some compounding pharmacies to either specialize further or transition towards FDA-approved products to mitigate regulatory risks and potentially achieve higher, more stable margins, similar to larger pharmaceutical companies.
• The substantial debt maturities in early 2026, representing a significant portion of total assets, are a critical liquidity concern that would be closely monitored by industry analysts, as such concentrations of near-term debt are not ideal and can impact financial flexibility compared to peers with more staggered debt profiles.

Management Changes

Corporate Governance

Legal Proceedings

• ImprimisRx, LLC, a subsidiary, filed a lawsuit against Ocular Science, Inc. and OSRX, Inc. for copyright infringement, trademark infringement, unfair competition, and false advertising. A jury found OSRX acted with malice, fraud, or oppression, willfully engaging in trademark infringement and unfair competition, awarding ImprimisRx, LLC a $34,900,000 jury verdict ($20,400,000 punitive, $14,500,000 actual damages). The company has not recognized any gains due to collection uncertainty.
• The company has faced multiple FDA warning letters and inspections (2017, 2020, 2022, 2024) related to alleged marketing activities, use of active pharmaceutical ingredients, and compounding practices at its New Jersey outsourcing facility (NJOF). Recent discussions with the federal government regarding the NJOF quality system and 2024 Inspection are now closed, following voluntary product recalls and remediation activities.

Related Party Transactions

• During the six months ended June 30, 2025, Mark L. Baum (CEO), Andrew R. Boll (CFO), and John P. Saharek (President of ImprimisRx) received shares of common stock upon the vesting of Performance Stock Units (PSUs) granted in April 2023. Shares were withheld for payroll tax obligations totaling $3,157,000 for Mr. Boll, $6,935,000 for Mr. Baum, and $2,528,000 for Mr. Saharek.
• In July 2025, Mark L. Baum, CEO, received 286,662 shares of common stock upon cashless exercise of options, with 127,346 shares withheld for the cashless exercise and 185,992 shares for payroll tax obligations totaling $6,897,000.
• In July 2025, Mark L. Baum, CEO, and Andrew R. Boll, CFO, were granted an aggregate of 1,295,249 performance stock units (2025 PSUs) subject to market-based and continued service conditions, with stock price targets ranging from $50 to $100 per share over a five-year term.

Stakeholder Impact

• **Shareholders:** Potential for significant dilution if future capital raises involve equity. The substantial debt maturities in early 2026 pose a material risk to shareholder value if refinancing is not secured on favorable terms or at all. Positive revenue growth and improved operating cash flow could enhance long-term value if debt issues are resolved.
• **Employees:** Continued stock-based compensation plans (2025 Incentive Stock and Awards Plan, RSU/PSU vesting) aim to attract and retain talent, aligning employee interests with company performance. However, the 'going concern' warning could create uncertainty regarding job security.
• **Customers:** The 'VEVYE Access for All' program aims to increase patient access and affordability, potentially benefiting dry eye patients. The strategic shift from compounded formulations to FDA-approved products (Project Beagle) may offer customers more standardized and regulated options, but could also mean changes in product availability for those reliant on discontinued compounded drugs.
• **Suppliers:** The company relies on a few main suppliers for active pharmaceutical ingredients, with 76% and 72% of purchases from three suppliers for the three and six months ended June 30, 2025, respectively. This concentration poses a supply chain risk if any of these suppliers face issues. Changes in U.S. trade policy and tariffs could increase costs for imported components, impacting supplier relationships and pricing.
• **Creditors:** The Oaktree Loan and 2026 Senior Notes, totaling $182,500,000, are due in early 2026, creating significant refinancing risk. The company's ability to secure new financing or sell assets will directly impact its ability to repay these creditors.

Next Steps

• Refinance the Oaktree Loan and the 2026 Notes during 2025 or soon thereafter.
• Commercialize BYQLOVI in the U.S. market, with expected availability in Q4 2025.
• Continue to review opportunities to reduce the size of the compounded formulary and transition ImprimisRx customers to FDA-approved products as part of Project Beagle.
• Develop, manufacture, and supply BYOOVIZ and OPUVIZ for commercialization in the U.S. market under the Samsung Agreement.

Key Dates

Recommendation

Harrow, Inc. demonstrates strong operational momentum with significant revenue growth in its branded segment and a positive shift in cash flow from operations. Strategic initiatives like the Samsung agreement and BYQLOVI acquisition are positive for future growth. However, the company faces a critical liquidity challenge with over $180 million in debt maturing in early 2026, explicitly raising 'substantial doubt about our ability to continue as a going concern' if refinancing or asset sales are unsuccessful. While management expresses confidence in refinancing, the uncertainty surrounding the terms and success of such efforts, coupled with ongoing regulatory risks, warrants a cautious 'hold' recommendation. Investors should await clarity on the debt resolution before making further investment decisions.

Keywords

Ophthalmology, Pharmaceuticals, SEC Filing, 10-Q, Financial Results, Debt Refinancing, Restricted Stock Units, Performance Stock Units, FDA Approval, Drug Commercialization, Compounding Pharmacy, BYQLOVI, VEVYE, IHEEZO, Oaktree Loan, Senior Notes, Regulatory Risk, Patient Access Program